1 Ocak 2021 Dergi makalesi Açık Erişim

Eskandari, Zahra; Bahadori, Fatemeh; Yenigun, Vildan Betul; Demiray, Mutlu; Eroglu, Mehmet Sayip; Kocyigit, Abdurrahim; Oner, Ebru Toksoy

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/229706</identifier>
  <creators>
    <creator>
      <creatorName>Eskandari, Zahra</creatorName>
      <givenName>Zahra</givenName>
      <familyName>Eskandari</familyName>
    </creator>
    <creator>
      <creatorName>Bahadori, Fatemeh</creatorName>
      <givenName>Fatemeh</givenName>
      <familyName>Bahadori</familyName>
      <affiliation>BezmialemVakif Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Vatan Str Adnan Menderes Blv, TR-34093 Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yenigun, Vildan Betul</creatorName>
      <givenName>Vildan Betul</givenName>
      <familyName>Yenigun</familyName>
      <affiliation>Bezmialem Vakif Univ, Fac Med, Dept Med Biochem, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Demiray, Mutlu</creatorName>
      <givenName>Mutlu</givenName>
      <familyName>Demiray</familyName>
      <affiliation>Medicana Int Istanbul Hosp, Dept Med Oncol, TR-34520 Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Eroglu, Mehmet Sayip</creatorName>
      <givenName>Mehmet Sayip</givenName>
      <familyName>Eroglu</familyName>
    </creator>
    <creator>
      <creatorName>Kocyigit, Abdurrahim</creatorName>
      <givenName>Abdurrahim</givenName>
      <familyName>Kocyigit</familyName>
      <affiliation>Bezmialem Vakif Univ, Fac Med, Dept Med Biochem, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Oner, Ebru Toksoy</creatorName>
      <givenName>Ebru Toksoy</givenName>
      <familyName>Oner</familyName>
      <affiliation>Marmara Univ, Dept Bioengn, IBSB Ind Biotechnol &amp; Syst Biol Res Grp, Goztepe Campus, TR-34722 Istanbul, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Levan Enhanced The Nf-Kappa B Suppression Activity Of An Oral Nano Plga-Curcumin Formulation In Breast Cancer Treatment</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2021</publicationYear>
  <dates>
    <date dateType="Issued">2021-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/229706</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.ijbiomac.2021.08.115</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Chemoresistance (CR) is one of the reasons why chemotherapy agents like Gemcitabine (GMC) remain insufficient in healing breast cancer. Activation of Nuclear Factor-kappa B (NF-kappa B) during chemotherapy is known as an important factor in the development of CR. The hydrophobic polyphenol curcumin is shown to inhibit NF-kappa B and hence CR. The aim of this work was to increase the poor bioavailability of curcumin by loading it into the nano-micelles made of Poly (Lactide-co-Glycolide) (PLGA) and levan, where levan as a natural fructose homopolymer makes the nano-micelle more stable and increases its uptake using the fructose moieties. In this study, a PLGA-levan-curcumin formulation (PLC) was designed and characterized. The size was measured as 154.16 +/- 1.45 nm with a 67.68% encapsulation efficiency (EE%). The incorporation between the components was approved. Levan made the nano-micelles stable for at least three months, increased their uptake, and led to a 10,000-fold increase in the solubility of curcumin. The enhanced bioavailability of curcumin reduced the NF-kappa B levels elevated by GMC, both in vitro and in vivo. The PLC showed a complete tumor treatment, while GMC only showed a rate of 52%. These point to the great potential of the PLC to be used simultaneously with chemotherapy.</description>
  </descriptions>
</resource>